<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395250</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-20150313</org_study_id>
    <nct_id>NCT02395250</nct_id>
  </id_info>
  <brief_title>Anti-GPC3 CAR T for Treating Patients With Advanced HCC</brief_title>
  <official_title>Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether autologous T cells bearing chimeric antigen
      receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients
      with relapsed or refractory hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events attributed to the administration of the anti-GPC3 CAR T cells</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>anti-GPC3 CAR T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-GPC3 CAR T</intervention_name>
    <arm_group_label>anti-GPC3 CAR T</arm_group_label>
    <other_name>CAR T cells redirected to Glypican-3 in cancer cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age of 18-70 years;

          2. Pathologically confirmed advanced hepatocellular carcinoma (HCC);

          3. ≥1 measurable target lesion per Response Evaluation Criteria in Solid Tumors version
             1.1 (RECIST v1.1);

          4. Tumor tissue positive for GPC3 expression per immunohistochemical staining (IHC)
             assay;

          5. Estimated survival &gt; 12 weeks;

          6. Child-Pugh grade A;

          7. ECOG performance score of 0-1;

          8. HBV-DNA &lt; 200 IU/mL if positive for HBsAg or HBcAb. Patients positive for HBsAg shall
             receive anti-viral treatment per &quot;The guideline of prevention and treatment for
             chronic hepatitis B: a 2015 update&quot;;

          9. Have adequate venous access for apheresis or venous blood collection;

         10. White blood cells ≥ 2.5 x 109/L, platelet ≥ 60×109/L, haemoglobin ≥ 9.0 g/dL,
             lymphocyte ≥ 0.4×109/L

         11. Serum albumin ≥ 30 g/dL, serum lipase and amylase≤1.5 upper limit of normal (ULN),
             serum creatinine ≤ 1.5 ULN and endogenous creatinine clearance ≥ 40mL/min, ALT and AST
             ≤ 5 ULN, Serum total bilirubin ≤ 2.5 ULN, Prothrombin Time is less than 4s longer than
             normal;

         12. Negative serum pregnancy test within 14 days before CAR T infusion, and with
             willingness to use reliable contraceptive methods to avoid pregnancy until 12 months
             after CAR T infusions for females of childbearing age; Having undergone sterilization
             procedure or with willingness to use reliable contraceptive methods to avoid pregnancy
             for males with female partner of childbearing age during the study;

         13. Able to understand and sign the informed consent form

        Exclusion criteria:

        If the patient meets any of the exclusion criteria, the patient must be excluded from the
        study.

          1. Pregnant or lactating female patients;

          2. Positive serum tests for HCV, HIV, or syphilis;

          3. Presence of HBV/HCV coinfection;

          4. Presence of any uncontrollable active infection, such as, but not limited to, active
             tuberculosis

          5. History of systemic administration of steroids (not including inhaled steroids), or
             other immunosuppressant drugs within 2 weeks before apheresis;

          6. History of allergy to immunotherapy and related drugs, or β-lactam antibiotics, or
             history of other severe allergy;

          7. History or current presence of hepatic encephalopathy;

          8. Presence of ascites with clinical significance that is defined as positive focused
             physical examination for ascites, or ascites that requires treatment intervention (not
             including any ascites shown on image examinations without the need for clinical
             intervention);

          9. ≥ 50% of normal liver occupied with HCC tumor tissue, or presence of tumor thrombus in
             the portal vein, or mesenteric vein, or inferior vena based on image analysis;

         10. Presence of HCC metastatic lesion in the central nervous system, or presence of other
             diseases of central nervous system with clinical significance;

         11. Presence of heart disease that requires treatment intervention, or poorly controlled
             hypertension (systolic pressure &gt; 160 mmHg, or diastolic pressure &gt; 100 mmHg);

         12. Presence of active auto-immune disease that requires immunosuppressant treatment;

         13. History of organ transplantation or currently on the waiting list for organ
             transplantation, including, but not limited to, liver transplantation;

         14. Anti-HCC therapies including, but not limited to, surgical resection, interventional
             therapy, radiation therapy, chemotherapy, and immunotherapy, within 2 weeks before
             apheresis;

         15. History of receiving anti-PD-1 or anti-PD-L1 monoclonal antibodies, or other
             immunotherapy;

         16. History of other malignancies in the past 5 years, or presence of other active
             malignancies (not including cervical cancer in situ and basal cell carcinomas);

         17. Presence of other serious diseases or conditions, including uncontrolled diabetes
             (HbA1c &gt; 7% with treatment); severe cardiac dysfunction with LVEF &lt; 45%; myocardial
             infarction, unstable angina, or unstable arrhythmia in the past 6 months pulmonary
             embolism; chronic obstructive pulmonary disease; interstitial lung disease; forced
             expiratory volume in 1 second (FEV1) &lt; 60%, gastric ulcer; history of gastrointestinal
             bleeding, or confirmed tendency for gastrointestinal bleeding;

         18. Determined by the investigator to be lack of compliance for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Zhai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Renji</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Cancer Institute</name>
      <address>
        <city>Xuhui</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2015</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

